ArticleInternational journal of molecular sciences2018
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- [Research square · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Preclinical Evaluation ofJournal of medicinal chemistry · 2025Article
- Review
- Preclinical Investigation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Therapeutic potential of [European journal of nuclear medicine and molecular imaging · 2024Article
- Chondroitin Sulfate Proteoglycan 4 Provides New Treatment Approach to Preventing Peritoneal Dissemination in Ovarian Cancer.International journal of molecular sciences · 2024Article
- Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.Nature communications · 2023Article
- CD46 targetedJournal of experimental & clinical cancer research : CR · 2023Article
- The application of radionuclide therapy for breast cancer.Frontiers in nuclear medicine · 2023Review
- Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models.Frontiers in chemistry · 2023Article
- Primary standardization ofApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2022Article
- CAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application.International journal of biological sciences · 2022Review
- Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?Frontiers in oncology · 2022Article
- Article
- Targeted α-therapy in non-prostate malignancies.European journal of nuclear medicine and molecular imaging · 2021Review
- A Novel Single-Step-LabeledMaterials (Basel, Switzerland) · 2021Article
- Treatment with Radiopharmaceuticals and Radionuclides in Breast Cancer: Current Options.European journal of breast health · 2021Review
- Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis. There is a clinical need for effective, targeted therapy strategies that destroy both differentiated TNBC cells and TNBC cancer initiating cells (CICs), as the latter are implicated in the metastasis and recurrence of TNBC. Chondroitin sulfate proteoglycan 4 (CSPG4) is overexpressed on differentiated tumor cells and CICs obtained from TNBC patient specimens, suggesting that CSPG4 may be a clinically relevant target for the imaging and therapy of TNBC. The purpose of this study was to determine whether α-particle radioimmunotherapy (RIT) targeting TNBC cells using the CSPG4-specific monoclonal antibody (mAb) 225.28 as a carrier was effective at eliminating TNBC tumors in preclinical models. To this end, mAb 225.28 labeled with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.